Trulicity

— THERAPEUTIC DISORDERS TREATED —
  • CHF and arrhythmias
  • Diabetes
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Trulicity Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Dulaglutide 0.75mg/0.5mL, 1.5mg/0.5mL, 3mg/0.5mL, 4.5mg/0.5mL; per pen; soln for SC inj.

    Pharmacological Class

    Glucagon-like peptide-1 (GLP-1) receptor agonist.

    How Supplied

    Single-dose pen—4

    Manufacturer

    Eli Lilly and Company

    Generic Availability

    NO

    Mechanism of Action

    Dulaglutide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Additionally, it also decreases glucagon secretion and slows gastric emptying.

    Trulicity Indications

    Indications

    To reduce the risk of major cardiovascular (CV) events (eg, CV death, non-fatal MI or non-fatal stroke) in adults with type 2 diabetes mellitus (T2DM) who have established CV disease or multiple CV risk factors. 

    Trulicity Dosage and Administration

    Adult

    Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. Initially 0.75mg once weekly; increase to 1.5mg once weekly if inadequate response. If additional glycemic control is needed, increase in 1.5mg increments after ≥4 weeks on the current dose; max 4.5mg once weekly.

    Children

    Not established.

    Trulicity Contraindications

    Contraindications

    History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

    Trulicity Boxed Warnings

    Boxed Warning

    Risk of thyroid C-cell tumors.

    Trulicity Warnings/Precautions

    Warnings/Precautions

    Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Monitor renal function when initiating or escalating dose, and in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.

    Trulicity Pharmacokinetics

    Metabolism

    Protein catabolism pathways.

    Elimination

    Half-life: ~5 days.

    Trulicity Interactions

    Interactions

    Concomitant insulin: administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.

    Trulicity Adverse Reactions

    Adverse Reactions

    Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.

    Trulicity Clinical Trials

    See Literature

    Trulicity Note

    Not Applicable

    Trulicity Patient Counseling

    See Literature

    Trulicity Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Dulaglutide 0.75mg/0.5mL, 1.5mg/0.5mL, 3mg/0.5mL, 4.5mg/0.5mL; per pen; soln for SC inj.

    Pharmacological Class

    Glucagon-like peptide-1 (GLP-1) receptor agonist.

    How Supplied

    Single-dose pen—4

    Manufacturer

    Eli Lilly and Company

    Generic Availability

    NO

    Mechanism of Action

    Dulaglutide activates the GLP-1 receptor, thereby increasing intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Additionally, it also decreases glucagon secretion and slows gastric emptying.

    Trulicity Indications

    Indications

    As adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). 

    Limitations of Use

    Not studied in patients with history of pancreatitis. Not for treating type 1 diabetes mellitus. Not recommended in patients with severe GI disease (including severe gastroparesis).

    Trulicity Dosage and Administration

    Adult

    Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥18yrs: initially 0.75mg once weekly; increase to 1.5mg once weekly if inadequate response. If additional glycemic control is needed, increase in 1.5mg increments after ≥4 weeks on the current dose; max 4.5mg once weekly.

    Children

    <10yrs: not established. Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥10yrs: initially 0.75mg once weekly. If additional glycemic control is needed, may increase to max 1.5mg once weekly after ≥4 weeks on the 0.75mg dose.

    Trulicity Contraindications

    Contraindications

    History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

    Trulicity Boxed Warnings

    Boxed Warning

    Risk of thyroid C-cell tumors.

    Trulicity Warnings/Precautions

    Warnings/Precautions

    Risk of thyroid C-cell tumors; inform patients of potential risk and symptoms. History of pancreatitis; consider other antidiabetics. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of diabetic retinopathy; monitor for progression. History of anaphylaxis or angioedema with other GLP-1 receptor agonist. Acute gallbladder disease (eg, cholelithiasis, cholecystitis). Perform gallbladder studies and clinical follow-up if cholelithiasis is suspected. Monitor renal function when initiating or escalating dose, and in renally-impaired patients reporting severe GI reactions. ESRD. Hepatic impairment. Pregnancy. Nursing mothers.

    Trulicity Pharmacokinetics

    Metabolism

    Protein catabolism pathways.

    Elimination

    Half-life: ~5 days.

    Trulicity Interactions

    Interactions

    Concomitant insulin: administer as separate injections not adjacent to each other. Increased risk of hypoglycemia with concomitant insulin secretagogues (eg, sulfonylureas) or insulin; may need lower dose of these. May affect absorption of concomitant oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.

    Trulicity Adverse Reactions

    Adverse Reactions

    Nausea, diarrhea, vomiting, abdominal pain, decreased appetite; pancreatitis, hypersensitivity reactions (discontinue if occur), acute kidney injury.

    Trulicity Clinical Trials

    See Literature

    Trulicity Note

    Not Applicable

    Trulicity Patient Counseling

    See Literature

    • Latest News Your top articles for Monday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More